Results of Meeting
Released
Released
Announcement PDF
ASX Announcement
Results of 2025 Annual General Meeting
SYDNEY Australia, 5 November 2025: In accordance with ASX Listing Rule 3.13.2 and section
251AA of the Corporations Act 2001 (Cth), the results of the Recce Pharmaceuticals Ltd (ASX:RCE,
FSE:R9Q) Annual General Meeting held today at 9:30am (AEDT) are attached.
All resolutions put to the Annual General Meeting were decided by way of poll.
About Recce Pharmaceuticals Ltd
Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives
designed to address the urgent global health problems of antibiotic-resistant superbugs.
Recce’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives:
RECCE® 327 (R327) as an intravenous and topical therapy that is being developed for the treatment of serious
and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their
superbug forms; RECCE® 435 (R435) as an orally administered therapy for bacterial infections; and RECCE®
529 (R529) for viral infections. Through their multi-layered mechanisms of action, Recce’s anti-infectives have
the potential to overcome the processes utilised by bacteria and viruses to overcome resistance – a current
challenge facing existing antibiotics.
The World Health Organization (WHO) added R327, R435, and R529 to its list of antibacterial products in
clinical development for priority pathogens, recognising Recce’s efforts to combat antimicrobial resistance.
The FDA granted R327 Qualified Infectious Disease Product designation under the Generating Antibiotic
Initiatives Now (GAIN) Act, providing Fast Track Designation and 10 years of market exclusivity post approval.
R327 is also included on The Pew Charitable Trusts’ Global New Antibiotics in Development Pipeline as the
sole synthetic polymer and sepsis drug candidate in development.
Recce wholly owns its automated manufacturing, supporting current clinical trials. Recce’s anti-infective
pipeline aims to address synergistic, unmet medical needs by leveraging its unique technologies.
This announcement has been approved for release by Recce Pharmaceuticals Board.
Disclosure of Proxy Votes
Recce Pharmaceuticals Ltd
Annual General Meeting
Wednesday, 05 November 2025
In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.
Automic
GPO Box 5193, Sydney, NSW 2001
P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)
F +61 (0)2 8583 3040 E hello@automic.com.au
ABN 27 152 260 814
Proxy Votes
Poll Results (if
applicable)
Results
Resolution
Decided by
Show of
Hands (S) or
Poll (P)
Total Number of
Proxy Votes
exercisable by
proxies validly
appointed
FOR AGAINST ABSTAIN
PROXY'S
DISCRETION
FOR AGAINST ABSTAIN OUTCOME
1 Adoption of Remuneration Report P 29,286,979
6,573,418
22.44%
21,009,393
71.74%
242,759
1,704,168
5.82%
14,699,907
19.32%
61,374,994
80.68%
242,759 -
2 Re-election of Dr John Prendergast as Director P 33,218,403
10,997,793
33.11%
20,506,942
61.73%
20,000
1,713,668
5.16%
59,499,383
74.37%
20,506,942
25.63%
20,000 Carried
3 Re-election of Dr Justin Ward as Director P 32,886,719
31,089,772
94.54%
83,279
0.25%
351,684
1,713,668
5.21%
79,591,362
99.90%
83,279
0.10%
351,684 Carried
4 ASX Listing Rule 7.1A Approval of Future Issue of
Securities
P 33,131,644
30,657,670
92.53%
760,306
2.29%
106,759
1,713,668
5.17%
38,632,304
48.34%
41,287,262
51.66%
106,759 Not Carried
5 Ratification of Prior Issue of Placement Shares P 33,043,127
31,149,360
94.27%
180,099
0.55%
195,276
1,713,668
5.19%
39,285,349
49.21%
40,545,700
50.79%
195,276 Not Carried
6 Ratification of Prior Issue of Warrants P 32,878,701
30,930,539
94.07%
231,494
0.70%
359,702
1,716,668
5.22%
39,024,528
48.98%
40,642,095
51.02%
359,702 Not Carried
Note: (a) As more than 25% of the votes cast on Resolution 1 were against the adoption of the 2025 Remuneration Report, this constitutes a ‘first strike’ under section 250U of the Corporations Act 2001 (Cth).
(a)
Share your feedback
Discover